Our evidence points to FBXO28 as the strongest candidate gene in the region: it is predicted to be a target of the regulatory variants, its expression in breast tumor tissue correlates with these variants, and its expression level also associates with breast cancer survival specifically in ER-positive, TP53-mutated breast cancer. Here, FBXO28 is linked to breast neoplasm.